101 Real-world analysis of the impact of pemetrexed in first-line maintenance (1LM) with immunotherapy (IO) for non-squamous (NSQ) advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking targetable mutations, prior to and during the COVID-19 pandemic
Real-world analyses of 1LM IO ± pemetrexed for NSQ a/ mNSCLC and how the COVID-19 pandemic reshaped treatment patterns and outcomes are lacking. This retrospective study characterised treatment patterns and their outcomes in this group of patients diagnosed in England prior to/during the COVID-19 pandemic.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Fabio Gomes, Niall Gilding, Vivian Tan, Katerina Christoforou, Joanne Rule, Amine Aziez, Adam Januszewski, Anna Minchom Tags: NSCLC Systemic Treatment Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | COVID-19 | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pandemics | Study